187 related articles for article (PubMed ID: 32178618)
21. Acute systemic sarcoidosis complicating ustekinumab therapy for chronic plaque psoriasis.
Powell JB; Matthews P; Rattehalli R; Woodhead F; Perkins P; Powell G; Szczecinska W; Gach JE
Br J Dermatol; 2015 Mar; 172(3):834-6. PubMed ID: 25141774
[No Abstract] [Full Text] [Related]
22. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
Helliwell PS; Gladman DD; Chakravarty SD; Kafka S; Karyekar CS; You Y; Campbell K; Sweet K; Kavanaugh A; Gensler LS
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32209721
[TBL] [Abstract][Full Text] [Related]
23. Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice.
Almirall M; Rodriguez J; Mateo L; Carrascosa JM; Notario J; Gallardo F
Clin Rheumatol; 2017 Feb; 36(2):439-443. PubMed ID: 27817126
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
[TBL] [Abstract][Full Text] [Related]
25. Worsening of Psoriatic Arthritis After Ustekinumab Treatment.
Onsun N; Yalcin B; Sallahoglu K; Rezvani A
Am J Ther; 2018; 25(3):e381-e382. PubMed ID: 29189317
[No Abstract] [Full Text] [Related]
26. The Paradoxical Induction of Crohn’s Disease Following Treatment of Psoriatic Arthritis With Etanercept.
Forouzandeh M; Vazquez T; Nouri K; Forouzandeh B
J Drugs Dermatol; 2019 Aug; 18(8):832-834. PubMed ID: 31424717
[TBL] [Abstract][Full Text] [Related]
27. Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy.
Christoforidou A; Goudakos J; Bobos M; Lefkaditis E; Vital V; Markou K
Am J Otolaryngol; 2013; 34(3):268-72. PubMed ID: 23357593
[TBL] [Abstract][Full Text] [Related]
28. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
Thibodaux RJ; Triche MW; Espinoza LR
Expert Opin Biol Ther; 2018 Jul; 18(7):821-827. PubMed ID: 29949399
[TBL] [Abstract][Full Text] [Related]
29. A review of ustekinumab in the treatment of psoriatic arthritis.
Roberts J; O'Rielly DD; Rahman P
Immunotherapy; 2018 Apr; 10(5):361-372. PubMed ID: 29439608
[TBL] [Abstract][Full Text] [Related]
30. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.
Čarija A; Ivić I; Marasović-Krstulović D; Puizina-Ivić N
Rheumatology (Oxford); 2015 Nov; 54(11):2114-6. PubMed ID: 26242857
[No Abstract] [Full Text] [Related]
31. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Gottlieb A; Menter A; Mendelsohn A; Shen YK; Li S; Guzzo C; Fretzin S; Kunynetz R; Kavanaugh A
Lancet; 2009 Feb; 373(9664):633-40. PubMed ID: 19217154
[TBL] [Abstract][Full Text] [Related]
32. New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study.
Asahina A; Umezawa Y; Momose M; Honda H; Yanaba K; Nakagawa H
J Dermatol; 2017 Dec; 44(12):1380-1384. PubMed ID: 28771778
[TBL] [Abstract][Full Text] [Related]
33. Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis.
Song GG; Lee YH
Z Rheumatol; 2018 Sep; 77(7):613-620. PubMed ID: 28791450
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
35. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial.
Kavanaugh A; Menter A; Mendelsohn A; Shen YK; Lee S; Gottlieb AB
Curr Med Res Opin; 2010 Oct; 26(10):2385-92. PubMed ID: 20831455
[TBL] [Abstract][Full Text] [Related]
36. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
[TBL] [Abstract][Full Text] [Related]
37. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.
Mugheddu C; Atzori L; Del Piano M; Lappi A; Pau M; Murgia S; Zucca I; Rongioletti F
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28833973
[TBL] [Abstract][Full Text] [Related]
38. Ustekinumab associated with flares of psoriatic arthritis.
Stamell EF; Kutner A; Viola K; Cohen SR
JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
[TBL] [Abstract][Full Text] [Related]
39. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.
Ahn CS; Dothard EH; Garner ML; Feldman SR; Huang WW
J Am Acad Dermatol; 2015 Sep; 73(3):420-8.e1. PubMed ID: 26184440
[TBL] [Abstract][Full Text] [Related]
40. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study.
Napolitano M; Balato N; Caso F; Costa L; Megna M; Cirillo T; Balato A; Scarpa R
Clin Exp Rheumatol; 2017; 35(1):137-140. PubMed ID: 27749221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
